Sanctura Accounts For 7.6% Of New Overactive Bladder Scripts By Urologists
This article was originally published in The Pink Sheet Daily
Executive Summary
Indevus/Pliva's overactive bladder product has gained 3% of new scripts overall since its August launch. Indevus plans to begin Phase III trials of Sanctura XR in mid-2005.
You may also be interested in...
No Pauses For Pagoclone: Indevus Moving To Phase III For Stuttering
The anxiolytic would be the first drug indicated for the condition.
No Pauses For Pagoclone: Indevus Moving To Phase III For Stuttering
The anxiolytic would be the first drug indicated for the condition.
Sanctura Growth Pushed By Urinary Incontinence Awareness, Pliva Says
Pliva says the recent addition of three new products to the urinary incontinence market is "positive" because of the increase in awareness of the condition. Sanctura has "almost 8%" of market share among urologists, a figure the company hopes will "trickle down" to general practitioners, Pliva says.